Intellia Therapeutics, Inc. (NTLA): Form 8-K/A filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 17:05 ET
- Event date
- 2026-11-12
- Accession no.
- 0001193125-26-460948
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Intellia shares lonvo-z regulatory review and commercial readiness update
Intellia furnished a presentation on lonvo-z for hereditary angioedema, including clinical data and commercial readiness. The presentation states that FDA accepted its biologics license application and granted priority review, with a PDUFA goal date of MARCH 10, 2027. The amendment corrects only the original report’s Item number and title.
- Intellia hosted “Readying Lonvo-z for Patients with HAE” on November 12, 2026.
- FDA accepted the lonvo-z BLA on SEPTEMBER 3, 2026, and granted priority review.
- The PDUFA goal date is MARCH 10, 2027.
- The amendment corrects only the original report’s Item number and title.
productregulatory
Items reported
- Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K/A | 8-K/A | ntla-20261112.htm |
| EX-99.1 | EX-99.1 | ntla-ex99_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.